The target audience and core patient demographic for NRx Pharmaceuticals comprise individuals suffering from severe psychiatric disorders, treatment-resistant depression, acute suicidal ideation, bipolar depression, and specific chronic respiratory conditions. Additionally, its commercial and clinical solutions cater to institutional healthcare providers, interventional psychiatry clinics, academic medical centers, military treatment facilities, and government defense health organizations seeking advanced neuroplasticity and rapid-acting central nervous system therapeutics.